Search Results

Under the collaboration and licensing agreement, Novo Nordisk and Neomorph are looking to discover, develop and commercialize novel molecular glue degraders for cardiometabolic and rare diseases.

Neomorph, Inc. today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degraders.

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.

Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets,’ announced the appointment of Bell Zhong as the company’s Chief Financial Officer.

Neomorph, Inc., a rapidly growing biotechnology company comprised of industry leading experts in the field of targeted protein degradation (TPD), today announced that it will participate in an upcoming virtual investor conference.

Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets’, announced that its board of directors has appointed Philip Chamberlain, D.Phil. as Chief Executive Officer.

Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system